Schizophrenia spectrum disorders arise from a complex interplay of inherited and noninherited factors. Family and twin studies establish a strong genetic contribution: Patrick F. Sullivan at the University of North Carolina and colleagues summarize evidence that heritability can be as high as around 80 percent, indicating that genetic differences explain a large portion of population-level risk but do not determine individual outcome.
Genetic architecture
Research by Stephan Ripke and the Psychiatric Genomics Consortium at the Broad Institute has shown that risk is largely polygenic: hundreds to thousands of common single-nucleotide variants each contribute a small increase in risk. Large genome-wide association studies identified over 100 genomic loci linked to schizophrenia, implicating genes involved in immune signaling, synaptic function, and neuronal development. Aggregating these small effects into polygenic risk scores can stratify population risk to a degree, but Alicia R. Martin at the Broad Institute has demonstrated that scores developed in European-ancestry samples perform poorly in other populations, highlighting a major equity limitation.
In contrast to common variants, rare variants and structural changes can have larger effects. Copy number variants such as the 22q11.2 deletion are among the highest-penetrance genetic risk factors recognized in clinical genetics and substantially increase the likelihood of developing psychosis. A landmark study by Anna Sekar and Steven A. McCarroll at the Broad Institute identified structural variation at the complement component 4 gene as a molecular mechanism that may link genetic variation to altered synaptic pruning during adolescence, offering a plausible biological pathway from DNA change to altered brain circuitry.
Mechanisms and consequences
Genetic discoveries point to convergent biological themes: altered synaptic pruning, immune-related processes, and disturbances in neurotransmitter systems such as glutamate and dopamine. These mechanistic insights help explain core clinical features—early adult onset, cognitive impairment, and episodic psychosis—and motivate new therapeutic targets. Sekar and McCarroll’s work on complement-mediated pruning, for example, provides a model for how immune-related genetic variation could produce lasting changes in cortical connectivity.
Gene–environment interaction is central to how genetic risk translates into lived illness. Robin M. Murray at King’s College London emphasizes that environmental exposures—perinatal complications, heavy adolescent cannabis use, social adversity, urban upbringing, and migration—interact with genetic vulnerability to modify risk and course. The cultural and territorial contexts of these exposures matter: patterns of stigma, health care access, and local substance use shape both expression and outcomes. Because most large genetic studies have focused on people of European ancestry, clinical translation risks leaving underserved populations behind, worsening disparities in diagnosis, prevention, and treatment.
Practically, genetic information currently complements but does not replace clinical assessment. Polygenic scores offer research utility and potential future screening tools, while high-penetrance variants inform genetic counseling and specialist care. Ongoing work at major centers such as the Broad Institute, University of North Carolina, and King’s College London continues to refine risk models and test biologically informed interventions. Understanding genetic contributors is essential but must be coupled with attention to environment, culture, and equitable research practices to improve outcomes for people across diverse communities.